Physician profile
Caroline E Carr
NPI 1083767693
$2,728.54
in general payments reported to CMS, 2019-2025
14 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.07 · 2023: $1,837 · 2024: $163 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,805 · Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,805.10 |
| Food and Beverage | $911.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,805.10 | 2023 | Da Vinci Surgical System |
| Abbvie INC. | $333.43 | 2023-2025 | |
| Revance Therapeutics, INC. | $99.21 | 2025 | Daxxify |
| Arcutis Biotherapeutics, INC. | $92.28 | 2025 | Zoryve |
| Ucb, INC. | $75.05 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $73.42 | 2025 | Sotyktu |
| Almirall LLC | $67.60 | 2025 | Seysara |
| Merz North America, INC. | $60.63 | 2024 | |
| Mayne Pharma Commercial LLC | $35.19 | 2025 | |
| Organon LLC | $30.21 | 2025 | |
| Janssen Biotech, INC. | $15.82 | 2025 | Tremfya |
| Galderma Laboratories, L.P. | $14.76 | 2025 | Dysport |
| Amgen INC. | $13.77 | 2025 | Otezla |
| Allergan, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.